-
Something wrong with this record ?
Natural Killer Cells in the Malignant Niche of Multiple Myeloma
O. Venglar, JR. Bago, B. Motais, R. Hajek, T. Jelinek
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- MeSH
- Biomarkers MeSH
- Killer Cells, Natural immunology metabolism MeSH
- Molecular Targeted Therapy MeSH
- Cytotoxicity, Immunologic MeSH
- Immunity MeSH
- Immunomodulation drug effects MeSH
- Humans MeSH
- Disease Management MeSH
- Multiple Myeloma diagnosis etiology metabolism therapy MeSH
- Disease Susceptibility MeSH
- Tumor Microenvironment drug effects immunology MeSH
- Prognosis MeSH
- Receptors, Natural Killer Cell genetics metabolism MeSH
- T-Lymphocyte Subsets immunology metabolism MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Natural killer (NK) cells represent a subset of CD3- CD7+ CD56+/dim lymphocytes with cytotoxic and suppressor activity against virus-infected cells and cancer cells. The overall potential of NK cells has brought them to the spotlight of targeted immunotherapy in solid and hematological malignancies, including multiple myeloma (MM). Nonetheless, NK cells are subjected to a variety of cancer defense mechanisms, leading to impaired maturation, chemotaxis, target recognition, and killing. This review aims to summarize the available and most current knowledge about cancer-related impairment of NK cell function occurring in MM.
Faculty of Medicine University of Ostrava Ostrava Czechia
Faculty of Science University of Ostrava Ostrava Czechia
Hematooncology Clinic University Hospital Ostrava Ostrava Czechia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011347
- 003
- CZ-PrNML
- 005
- 20220506131108.0
- 007
- ta
- 008
- 220425s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fimmu.2021.816499 $2 doi
- 035 __
- $a (PubMed)35087536
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Venglar, Ondrej $u Faculty of Science, University of Ostrava, Ostrava, Czechia $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Hematooncology Clinic, University Hospital Ostrava, Ostrava, Czechia
- 245 10
- $a Natural Killer Cells in the Malignant Niche of Multiple Myeloma / $c O. Venglar, JR. Bago, B. Motais, R. Hajek, T. Jelinek
- 520 9_
- $a Natural killer (NK) cells represent a subset of CD3- CD7+ CD56+/dim lymphocytes with cytotoxic and suppressor activity against virus-infected cells and cancer cells. The overall potential of NK cells has brought them to the spotlight of targeted immunotherapy in solid and hematological malignancies, including multiple myeloma (MM). Nonetheless, NK cells are subjected to a variety of cancer defense mechanisms, leading to impaired maturation, chemotaxis, target recognition, and killing. This review aims to summarize the available and most current knowledge about cancer-related impairment of NK cell function occurring in MM.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a cytotoxicita imunologická $7 D003602
- 650 _2
- $a management nemoci $7 D019468
- 650 _2
- $a náchylnost k nemoci $7 D004198
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunita $7 D007109
- 650 _2
- $a imunomodulace $x účinky léků $7 D056747
- 650 _2
- $a buňky NK $x imunologie $x metabolismus $7 D007694
- 650 _2
- $a cílená molekulární terapie $7 D058990
- 650 _2
- $a mnohočetný myelom $x diagnóza $x etiologie $x metabolismus $x terapie $7 D009101
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a receptory buněk NK $x genetika $x metabolismus $7 D055607
- 650 _2
- $a T-lymfocyty - podskupiny $x imunologie $x metabolismus $7 D016176
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a nádorové mikroprostředí $x účinky léků $x imunologie $7 D059016
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bago, Julio Rodriguez $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Hematooncology Clinic, University Hospital Ostrava, Ostrava, Czechia
- 700 1_
- $a Motais, Benjamin $u Faculty of Science, University of Ostrava, Ostrava, Czechia $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia
- 700 1_
- $a Hajek, Roman $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Hematooncology Clinic, University Hospital Ostrava, Ostrava, Czechia
- 700 1_
- $a Jelinek, Tomas $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Hematooncology Clinic, University Hospital Ostrava, Ostrava, Czechia
- 773 0_
- $w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 12, č. - (2021), s. 816499
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35087536 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506131100 $b ABA008
- 999 __
- $a ok $b bmc $g 1789101 $s 1162545
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 12 $c - $d 816499 $e 20220111 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
- LZP __
- $a Pubmed-20220425
